FDA is advised to reject wider use of Amgen's Xgeva

02/8/2012 | Reuters

An expert panel urged the FDA not to approve Amgen's Xgeva for delaying the spread of prostate cancer to the bone, saying the drug's benefits do not outweigh the risk of developing osteonecrosis of the jaw. Xgeva provides a meaningful benefit, and is being tested against other cancers, including breast, lung and multiple myeloma, Amgen said. The FDA will issue a final ruling by April 26.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park